Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase II, Multi-site, Randomized, Open-label, Trial of Pumitamig in Combination With Chemotherapy in Patients With Metastatic Pancreatic Cancer

NCT07255404 is registered in ClinicalTrials.gov with BioNTech SE as lead sponsor.

NCT NCT07255404
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07255404 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase II, Multi-site, Randomized, Open-label, Trial of Pumitamig in Combination With Chemotherapy in Patients With Metastatic Pancreatic Cancer
Lead sponsor
BioNTech SE
Phase
Phase 2
Overall status
Recruiting
Start date
December 4, 2025
Completion date
August 31, 2028
Enrollment
105 (estimated)
Sites
24

Conditions

As the registry lists them; a condition with its own page is linked.

pancreatic ductal adenocarcinoma (pdac)